Skip to main content
Erschienen in: Advances in Therapy 4/2018

Open Access 07.03.2018 | Practical Approach

Recognizing Gynecological Cancer in Primary Care: Risk Factors, Red Flags, and Referrals

verfasst von: Garth Funston, Helena O’Flynn, Neil A. J. Ryan, Willie Hamilton, Emma J. Crosbie

Erschienen in: Advances in Therapy | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Early diagnosis of symptomatic gynecological cancer is likely to improve patient outcomes, including survival. The primary care practitioner has a key role to play in this—they must recognize the symptoms and signs of gynecological cancer and make prompt evidence-based decisions regarding further investigation and referral. However, this is often difficult as many of the symptoms of gynecological cancers are nonspecific and are more likely to be caused by benign rather than malignant disease. As primary care is generally the first point of patient contact, those working in this setting usually encounter cancer patients at an earlier, and possibly less symptomatic, stage than practitioners in secondary care. Despite these challenges, research has improved our understanding of the symptoms patients present to primary care with, and a range of tests and referral pathways now exist in the UK and other countries to aid early diagnosis. Primary care practitioners can also play a key role in gynecological cancer prevention. A significant proportion of gynecological cancer is preventable either through lifestyle changes such as weight loss, or, for cervical cancer, vaccination and/or engagement with screening programs. Primary care provides an excellent opportunity to discuss cancer risk with patients and to promote risk reduction strategies and lifestyle change. In this article, the first in a series discussing cancer detection in primary care, we concentrate on gynecological cancer and focus on the three most common forms that a primary care practitioner is likely to encounter: ovarian, endometrial, and cervical cancer. We outline key risk factors, briefly discuss prevention and screening strategies, and offer practical guidance on the recognition of symptoms and signs and the investigation and referral of women with suspected cancer. While this article is written from a UK primary care perspective, much of what is discussed will be of relevance to those working in other healthcare systems.
Literatur
3.
Zurück zum Zitat Lyratzopoulos G, Wardle J, Rubin G. Rethinking diagnostic delay in cancer: how difficult is the diagnosis? BMJ. 2014;349:g7400.CrossRefPubMed Lyratzopoulos G, Wardle J, Rubin G. Rethinking diagnostic delay in cancer: how difficult is the diagnosis? BMJ. 2014;349:g7400.CrossRefPubMed
4.
Zurück zum Zitat Maringe C, Walters S, Butler J, et al. Stage at diagnosis and ovarian cancer survival: evidence from the international cancer benchmarking partnership. Gynecol Oncol. 2012;127:75–82.CrossRefPubMed Maringe C, Walters S, Butler J, et al. Stage at diagnosis and ovarian cancer survival: evidence from the international cancer benchmarking partnership. Gynecol Oncol. 2012;127:75–82.CrossRefPubMed
5.
Zurück zum Zitat Hamilton W, Stapley S, Campbell C, et al. For which cancers might patients benefit most from expedited symptomatic diagnosis? Construction of a ranking order by a modified Delphi technique. BMC Cancer. 2015;15:820.CrossRefPubMedPubMedCentral Hamilton W, Stapley S, Campbell C, et al. For which cancers might patients benefit most from expedited symptomatic diagnosis? Construction of a ranking order by a modified Delphi technique. BMC Cancer. 2015;15:820.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Neal RD, Tharmanathan P, France B, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Syst Rev Br J Cancer. 2015;112:S92–107.CrossRef Neal RD, Tharmanathan P, France B, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Syst Rev Br J Cancer. 2015;112:S92–107.CrossRef
7.
Zurück zum Zitat Sundar S, Neal R, Kehoe E. Diagnosis of ovarian cancer. BMJ. 2015;351:h5543. Sundar S, Neal R, Kehoe E. Diagnosis of ovarian cancer. BMJ. 2015;351:h5543.
10.
Zurück zum Zitat Watson P, Vasen HFA, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer. 2008;123:444–9.CrossRefPubMedPubMedCentral Watson P, Vasen HFA, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer. 2008;123:444–9.CrossRefPubMedPubMedCentral
11.
12.
Zurück zum Zitat Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK collaborative trial of ovarian cancer screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387:945–56.CrossRefPubMedPubMedCentral Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK collaborative trial of ovarian cancer screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387:945–56.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004;291:2705–12.CrossRefPubMed Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004;291:2705–12.CrossRefPubMed
14.
Zurück zum Zitat Hamilton W, Peters TJ, Bankhead C, Sharp D. Risk of ovarian cancer in women with symptoms in primary care: population based case–control study. BMJ. 2009;339:b2998.CrossRefPubMedPubMedCentral Hamilton W, Peters TJ, Bankhead C, Sharp D. Risk of ovarian cancer in women with symptoms in primary care: population based case–control study. BMJ. 2009;339:b2998.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Bankhead CR, Collins C, Stokes-Lampard H, et al. Identifying symptoms of ovarian cancer: a qualitative and quantitative study. BJOG. 2008;115:1008–14.CrossRefPubMedPubMedCentral Bankhead CR, Collins C, Stokes-Lampard H, et al. Identifying symptoms of ovarian cancer: a qualitative and quantitative study. BJOG. 2008;115:1008–14.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Vine MF, Calingaert B, Berchuck A, Schildkraut JM. Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls. Gynecol Oncol. 2003;90:75–82.CrossRefPubMed Vine MF, Calingaert B, Berchuck A, Schildkraut JM. Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls. Gynecol Oncol. 2003;90:75–82.CrossRefPubMed
17.
Zurück zum Zitat Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer. 2000;89:2068–75.CrossRefPubMed Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer. 2000;89:2068–75.CrossRefPubMed
19.
Zurück zum Zitat Fischerova D. Ultrasound scanning of the pelvis and abdomen for staging of gynecological tumors: a review. Ultrasound Obstet Gynecol. 2011;38:246–66.CrossRefPubMed Fischerova D. Ultrasound scanning of the pelvis and abdomen for staging of gynecological tumors: a review. Ultrasound Obstet Gynecol. 2011;38:246–66.CrossRefPubMed
22.
Zurück zum Zitat Moss EL, Moran A, Reynolds TM, Stokes-Lampard H. Views of general practitioners on the role of CA125 in primary care to diagnose ovarian cancer. BMC Womens Health. 2013;13:8.CrossRefPubMedPubMedCentral Moss EL, Moran A, Reynolds TM, Stokes-Lampard H. Views of general practitioners on the role of CA125 in primary care to diagnose ovarian cancer. BMC Womens Health. 2013;13:8.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Banks J, Hollinghurst S, Bigwood L, et al. Preferences for cancer investigation: a vignette-based study of primary-care attendees. Lancet Oncol. 2014;15:232–40.CrossRefPubMed Banks J, Hollinghurst S, Bigwood L, et al. Preferences for cancer investigation: a vignette-based study of primary-care attendees. Lancet Oncol. 2014;15:232–40.CrossRefPubMed
30.
Zurück zum Zitat Okuda T, Sekizawa A, Purwosunu Y, et al. Genetics of endometrial cancers. Obstet Gynecol Int. 2010;2010:1–8.CrossRef Okuda T, Sekizawa A, Purwosunu Y, et al. Genetics of endometrial cancers. Obstet Gynecol Int. 2010;2010:1–8.CrossRef
31.
Zurück zum Zitat Maxwell GL, Schildkraut JM, Calingaert B, et al. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol. 2006;103:535–40.CrossRefPubMed Maxwell GL, Schildkraut JM, Calingaert B, et al. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol. 2006;103:535–40.CrossRefPubMed
32.
Zurück zum Zitat Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78.CrossRefPubMed Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78.CrossRefPubMed
33.
Zurück zum Zitat Bhaskaran K, Douglas I, Forbes H, et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet. 2014;384:755–65.CrossRefPubMedPubMedCentral Bhaskaran K, Douglas I, Forbes H, et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet. 2014;384:755–65.CrossRefPubMedPubMedCentral
35.
36.
Zurück zum Zitat Nieman KM, Romero IL, Van Houten B, Lengyel E. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta Mol Cell Biol Lipids. 2013;1831:1533–41.CrossRef Nieman KM, Romero IL, Van Houten B, Lengyel E. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta Mol Cell Biol Lipids. 2013;1831:1533–41.CrossRef
37.
Zurück zum Zitat Luo J, Beresford S, Chen C, et al. Association between diabetes, diabetes treatment and risk of developing endometrial cancer. Br J Cancer. 2014;111:1432–9.CrossRefPubMedPubMedCentral Luo J, Beresford S, Chen C, et al. Association between diabetes, diabetes treatment and risk of developing endometrial cancer. Br J Cancer. 2014;111:1432–9.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Jacobs I, Gentry-Maharaj A, Burnell M, et al. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case–control study within the UKCTOCS cohort. Lancet Oncol. 2011;12:38–48.CrossRefPubMed Jacobs I, Gentry-Maharaj A, Burnell M, et al. Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case–control study within the UKCTOCS cohort. Lancet Oncol. 2011;12:38–48.CrossRefPubMed
39.
Zurück zum Zitat Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome. JAMA. 2006;296:1507.CrossRefPubMed Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome. JAMA. 2006;296:1507.CrossRefPubMed
40.
Zurück zum Zitat Walker S, Hyde C, Hamilton W. Risk of uterine cancer in symptomatic women in primary care: case–control study using electronic records. Br J Gen Pract. 2013;63:643–8.CrossRef Walker S, Hyde C, Hamilton W. Risk of uterine cancer in symptomatic women in primary care: case–control study using electronic records. Br J Gen Pract. 2013;63:643–8.CrossRef
41.
Zurück zum Zitat McBride D, Hardoon S, Walters K, Gilmour S, Raine R. Explaining variation in referral from primary to secondary care: cohort study. BMJ. 2010;341:c6267.CrossRefPubMedPubMedCentral McBride D, Hardoon S, Walters K, Gilmour S, Raine R. Explaining variation in referral from primary to secondary care: cohort study. BMJ. 2010;341:c6267.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat ACOG. CO557: Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Obstet Gynecol. 2013;121:891–6. ACOG. CO557: Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Obstet Gynecol. 2013;121:891–6.
43.
Zurück zum Zitat Niksic M, Rachet B, Warburton FG, et al. Cancer symptom awareness and barriers to symptomatic presentation in England—are we clear on cancer? Br J Cancer. 2015;113:533–42.CrossRefPubMedPubMedCentral Niksic M, Rachet B, Warburton FG, et al. Cancer symptom awareness and barriers to symptomatic presentation in England—are we clear on cancer? Br J Cancer. 2015;113:533–42.CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Power E, Wardle J. Change in public awareness of symptoms and perceived barriers to seeing a doctor following be clear on cancer campaigns in England. Br J Cancer. 2015;112:S22–6.CrossRefPubMedPubMedCentral Power E, Wardle J. Change in public awareness of symptoms and perceived barriers to seeing a doctor following be clear on cancer campaigns in England. Br J Cancer. 2015;112:S22–6.CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22:35–9.CrossRef Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22:35–9.CrossRef
46.
Zurück zum Zitat Sankaranarayanan R. Screening for cancer in low- and middle-income countries. Ann Glob Health. 2014;80:412–7.CrossRefPubMed Sankaranarayanan R. Screening for cancer in low- and middle-income countries. Ann Glob Health. 2014;80:412–7.CrossRefPubMed
47.
Zurück zum Zitat Zhou Y, Ga A, Hamilton W, et al. Defining, measuring and preventing the diagnosis of cancer as an emergency: a critical review of current evidence. Nat Publ Gr. 2016;14:1–35. Zhou Y, Ga A, Hamilton W, et al. Defining, measuring and preventing the diagnosis of cancer as an emergency: a critical review of current evidence. Nat Publ Gr. 2016;14:1–35.
49.
Zurück zum Zitat Ferlay J, Soerjomataram I EM. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer. Ferlay J, Soerjomataram I EM. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer.
53.
Zurück zum Zitat Small W, Bacon MA, Bajaj A, et al. Cervical cancer: a global health crisis. Cancer. 2017;123:2404–12.CrossRefPubMed Small W, Bacon MA, Bajaj A, et al. Cervical cancer: a global health crisis. Cancer. 2017;123:2404–12.CrossRefPubMed
54.
Zurück zum Zitat Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013;17:S1–27.CrossRefPubMed Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2013;17:S1–27.CrossRefPubMed
55.
Zurück zum Zitat Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013;382:889–99.CrossRefPubMed Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013;382:889–99.CrossRefPubMed
56.
Zurück zum Zitat International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007;370:1609–21.CrossRef International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007;370:1609–21.CrossRef
58.
Zurück zum Zitat Blitz S, Baxter J, Raboud J, et al. Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus infection and cervical cytopathologic findings in HIV-positive and high-risk HIV-negative women. J Infect Dis. 2013;208:454–62.CrossRefPubMed Blitz S, Baxter J, Raboud J, et al. Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus infection and cervical cytopathologic findings in HIV-positive and high-risk HIV-negative women. J Infect Dis. 2013;208:454–62.CrossRefPubMed
59.
Zurück zum Zitat Low EL, Simon AE, Lyons J, Romney-Alexander D, Waller J. What do British women know about cervical cancer symptoms and risk factors? Eur J Cancer. 2012;48:3001–8.CrossRefPubMed Low EL, Simon AE, Lyons J, Romney-Alexander D, Waller J. What do British women know about cervical cancer symptoms and risk factors? Eur J Cancer. 2012;48:3001–8.CrossRefPubMed
60.
Zurück zum Zitat McSherry LA, Dombrowski SU, Francis JJ, et al. “It”s a can of worms’: understanding primary care practitioners’ behaviours in relation to HPV using the theoretical domains framework. Implement Sci. 2012;7:73.CrossRefPubMedPubMedCentral McSherry LA, Dombrowski SU, Francis JJ, et al. “It”s a can of worms’: understanding primary care practitioners’ behaviours in relation to HPV using the theoretical domains framework. Implement Sci. 2012;7:73.CrossRefPubMedPubMedCentral
61.
Zurück zum Zitat Hendry M, Pasterfield D, Gollins S, et al. Talking about human papillomavirus and cancer: development of consultation guides through lay and professional stakeholder coproduction using qualitative, quantitative and secondary data. BMJ Open. 2017;7:e015413.CrossRefPubMedPubMedCentral Hendry M, Pasterfield D, Gollins S, et al. Talking about human papillomavirus and cancer: development of consultation guides through lay and professional stakeholder coproduction using qualitative, quantitative and secondary data. BMJ Open. 2017;7:e015413.CrossRefPubMedPubMedCentral
63.
Zurück zum Zitat Stapley S, Hamilton W. Gynaecological symptoms reported by young women: examining the potential for earlier diagnosis of cervical cancer. Fam Pract. 2011;28:592–8.CrossRefPubMed Stapley S, Hamilton W. Gynaecological symptoms reported by young women: examining the potential for earlier diagnosis of cervical cancer. Fam Pract. 2011;28:592–8.CrossRefPubMed
64.
Zurück zum Zitat Lim AW, Ramirez AJ, Hamilton W, et al. Delays in diagnosis of young females with symptomatic cervical cancer in England: an interview-based study. Br J Gen Pract. 2014;64:e602–10.CrossRefPubMedPubMedCentral Lim AW, Ramirez AJ, Hamilton W, et al. Delays in diagnosis of young females with symptomatic cervical cancer in England: an interview-based study. Br J Gen Pract. 2014;64:e602–10.CrossRefPubMedPubMedCentral
65.
Zurück zum Zitat Lim AWW, Sasieni P, Hamilton W, Stapley S, Hollingworth A. Performance characteristics of visualising the cervix in symptomatic young females: a review of primary care records in females with and without cervical cancer. Br J Gen Pract. 2016;66:e189–92.CrossRefPubMedPubMedCentral Lim AWW, Sasieni P, Hamilton W, Stapley S, Hollingworth A. Performance characteristics of visualising the cervix in symptomatic young females: a review of primary care records in females with and without cervical cancer. Br J Gen Pract. 2016;66:e189–92.CrossRefPubMedPubMedCentral
67.
Zurück zum Zitat Lim AW, Landy R, Castanon A, et al. Cytology in the diagnosis of cervical cancer in symptomatic young women: a retrospective review. Br J Gen Pract. 2016;66:e871–9.CrossRefPubMedPubMedCentral Lim AW, Landy R, Castanon A, et al. Cytology in the diagnosis of cervical cancer in symptomatic young women: a retrospective review. Br J Gen Pract. 2016;66:e871–9.CrossRefPubMedPubMedCentral
69.
Zurück zum Zitat Kelly RS, Patnick J, Kitchener HC, Moss SM. HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. Br J Cancer. 2011;105:983–8.CrossRefPubMedPubMedCentral Kelly RS, Patnick J, Kitchener HC, Moss SM. HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. Br J Cancer. 2011;105:983–8.CrossRefPubMedPubMedCentral
70.
Zurück zum Zitat Public Health England. NHS cervical screening programme: colposcopy and programme management. 3rd ed. London: Public Health England; 2016. Public Health England. NHS cervical screening programme: colposcopy and programme management. 3rd ed. London: Public Health England; 2016.
71.
Zurück zum Zitat Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:524–32.CrossRefPubMed Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:524–32.CrossRefPubMed
72.
Zurück zum Zitat Kisser A, Zechmeister-Koss I. A systematic review of p16/Ki-67 immuno-testing for triage of low grade cervical cytology. BJOG. 2015;122:64–70.CrossRefPubMed Kisser A, Zechmeister-Koss I. A systematic review of p16/Ki-67 immuno-testing for triage of low grade cervical cytology. BJOG. 2015;122:64–70.CrossRefPubMed
73.
Zurück zum Zitat Arbyn M, Kyrgiou M, Simoens C, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ. 2008;337:a1284.CrossRefPubMedPubMedCentral Arbyn M, Kyrgiou M, Simoens C, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ. 2008;337:a1284.CrossRefPubMedPubMedCentral
74.
Zurück zum Zitat Berenson AB, Hirth JM, Chang M. Change in human papillomavirus prevalence among US women aged 18–59 years, 2009–2014. Obstet Gynecol. 2017;130:693–701.CrossRefPubMed Berenson AB, Hirth JM, Chang M. Change in human papillomavirus prevalence among US women aged 18–59 years, 2009–2014. Obstet Gynecol. 2017;130:693–701.CrossRefPubMed
75.
Zurück zum Zitat Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis. 2016;16:1154–68.CrossRefPubMed Wheeler CM, Skinner SR, Del Rosario-Raymundo MR, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis. 2016;16:1154–68.CrossRefPubMed
76.
Zurück zum Zitat Møller H, Gildea C, Meechan D, et al. Use of the English urgent referral pathway for suspected cancer and mortality in patients with cancer: cohort study. BMJ. 2015;351:h5102.CrossRefPubMedPubMedCentral Møller H, Gildea C, Meechan D, et al. Use of the English urgent referral pathway for suspected cancer and mortality in patients with cancer: cohort study. BMJ. 2015;351:h5102.CrossRefPubMedPubMedCentral
Metadaten
Titel
Recognizing Gynecological Cancer in Primary Care: Risk Factors, Red Flags, and Referrals
verfasst von
Garth Funston
Helena O’Flynn
Neil A. J. Ryan
Willie Hamilton
Emma J. Crosbie
Publikationsdatum
07.03.2018
Verlag
Springer Healthcare
Erschienen in
Advances in Therapy / Ausgabe 4/2018
Print ISSN: 0741-238X
Elektronische ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-018-0683-3

Weitere Artikel der Ausgabe 4/2018

Advances in Therapy 4/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Ist Fasten vor Koronarinterventionen wirklich nötig?

Wenn Eingriffe wie eine Koronarangiografie oder eine Koronarangioplastie anstehen, wird häufig empfohlen, in den Stunden zuvor nüchtern zu bleiben. Ein französisches Forscherteam hat diese Maßnahme hinterfragt.

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

04.06.2024 Typ-2-Diabetes Nachrichten

Wenn ältere Menschen mit Typ-2-Diabetes Schwierigkeiten beim Beschaffen und Zubereiten von Mahlzeiten haben, geht dies mit einem deutlich gesteigerten Risiko für schwere Hypoglykämien einher.

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

03.06.2024 Semaglutid Nachrichten

Der GLP-1-Agonist Semaglutid hat in der FLOW-Studie bewiesen, dass sich damit die Progression chronischer Nierenerkrankungen bei Patienten mit Typ-2-Diabetes bremsen lässt. Auch in kardiovaskulärer Hinsicht war die Therapie erfolgreich.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.